Exact Mass: 517.1848912
Exact Mass Matches: 517.1848912
Found 65 metabolites which its exact mass value is equals to given mass value 517.1848912
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Cys Cys His Arg
Cys Cys Arg His
Cys His Cys Arg
Cys His Met Gln
C19H31N7O6S2 (517.1777146000001)
Cys His Gln Met
C19H31N7O6S2 (517.1777146000001)
Cys His Arg Cys
Cys Met His Gln
C19H31N7O6S2 (517.1777146000001)
Cys Met Gln His
C19H31N7O6S2 (517.1777146000001)
Cys Gln His Met
C19H31N7O6S2 (517.1777146000001)
Cys Gln Met His
C19H31N7O6S2 (517.1777146000001)
Cys Arg Cys His
Cys Arg His Cys
Naltrexone-3-glucuronide
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
His Cys Cys Arg
His Cys Met Gln
C19H31N7O6S2 (517.1777146000001)
His Cys Gln Met
C19H31N7O6S2 (517.1777146000001)
His Cys Arg Cys
His Met Cys Gln
C19H31N7O6S2 (517.1777146000001)
His Met Gln Cys
C19H31N7O6S2 (517.1777146000001)
His Gln Cys Met
C19H31N7O6S2 (517.1777146000001)
His Gln Met Cys
C19H31N7O6S2 (517.1777146000001)
His Arg Cys Cys
Met Cys His Gln
C19H31N7O6S2 (517.1777146000001)
Met Cys Gln His
C19H31N7O6S2 (517.1777146000001)
Met His Cys Gln
C19H31N7O6S2 (517.1777146000001)
Met His Gln Cys
C19H31N7O6S2 (517.1777146000001)
Met Gln Cys His
C19H31N7O6S2 (517.1777146000001)
Met Gln His Cys
C19H31N7O6S2 (517.1777146000001)
Gln Cys His Met
C19H31N7O6S2 (517.1777146000001)
Gln Cys Met His
C19H31N7O6S2 (517.1777146000001)
Gln His Cys Met
C19H31N7O6S2 (517.1777146000001)
Gln His Met Cys
C19H31N7O6S2 (517.1777146000001)
Gln Met Cys His
C19H31N7O6S2 (517.1777146000001)
Gln Met His Cys
C19H31N7O6S2 (517.1777146000001)
Arg Cys Cys His
Arg Cys His Cys
Arg His Cys Cys
2-Methyl-2-propanyl 4-(6-{[5-bromo-4-(cyclopentylamino)-2-pyrimid inyl]amino}-3-pyridinyl)-1-piperazinecarboxylate
N(5)-[amino(sulfoamino)phosphoryl]-L-ornithyl-L-alanyl-L-arginine
(2S)-2-[[(2S)-2-[[(2S)-5-[[amino-(sulfonatoamino)phosphoryl]amino]-2-azaniumylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneazaniumyl)pentanoate
[(1S,2S)-cyclohexane-1,2-diamine-kappa(2)N,N](5,6-dimethyl-1,10-phenanthroline-kappa(2)N(1),N(10))platinum(2+)
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(3-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-2-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(3-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(3-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(3-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
(2E)-3-ethyl-2-[(E)-3-(3-ethyl-4,5-diphenyl-1,3-thiazol-3-ium-2-yl)prop-2-enylidene]benzo[g][1,3]benzothiazole
Phaseolotoxin
A tripeptide resulting from the formal condensation of the carboxy group of N(5)-[amino(sulfoamino)phosphoryl]-L-ornithine with the N-terminal amino group of L-alanyl-L-arginine. A toxin produced by cultured Pseudomonas syringae, the causal agent of halo blight disease in bean plants.
AZD3147
AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K[1]. AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K[1].